A prospective cohort study of 1,483 patients transplanted for myeloid malignancies, showed significantly better two-year survival in IV-Bu recipients compared to TBI recipients: 56% vs. 48%, respectively (p=0.019).
IV Busulfan Better Than TBI in Pre-Transplant Conditioning
Oct 2013